The latest price target for InspireMD (NASDAQ:NSPR) was reported by Piper Sandler on September 17, 2024. The analyst firm set a price target for $4.50 expecting NSPR to rise to within 12 months (a possible 65.43% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for InspireMD (NASDAQ:NSPR) was provided by Piper Sandler, and InspireMD reiterated their overweight rating.

There is no last upgrade for InspireMD

There is no last downgrade for InspireMD.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of InspireMD, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for InspireMD was filed on September 17, 2024 so you should expect the next rating to be made available sometime around September 17, 2025.

While ratings are subjective and will change, the latest InspireMD (NSPR) rating was a reiterated with a price target of $4.50 to $4.50. The current price InspireMD (NSPR) is trading at is $2.72, which is out of the analyst’s predicted range.